These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9480509)

  • 41. Contemporary treatment of high-risk localized prostate cancer.
    Tareen B; Kimmel J; Huang WC
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1069-76. PubMed ID: 20645696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The role of neoadjuvant treatment prior to radical prostatectomy].
    Sassine AM; Schulman C
    Acta Urol Belg; 1992; 60(3):61-71. PubMed ID: 1492635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Organ preservation in the management of prostatic cancer.
    Cellini N; Luzi S; Morganti AG; Leone MV; Mattiucci GC
    Rays; 1997; 22(3):467-71. PubMed ID: 9446952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
    Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
    Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbon ion radiotherapy for treatment of prostate cancer and subsequent outcomes after biochemical failure.
    Shimazaki J; Tsuji H; Ishikawa H; Okada T; Akakura K; Suzuki H; Harada M; Tsujii H
    Anticancer Res; 2010 Dec; 30(12):5105-11. PubMed ID: 21187497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose.
    Lilleby W; Dale E; Olsen DR; Gude U; Fosså SD
    Acta Oncol; 2003; 42(1):10-4. PubMed ID: 12665325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
    Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
    Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate].
    Richaud P; Salem N; Gaston R; Mauriac L; Chacon B; Bussières E
    Cancer Radiother; 1998; 2(1):27-33. PubMed ID: 9749093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormonal therapy and radiation for prostate cancer: is it safe?
    Nanda A; D'Amico AV
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):979-81. PubMed ID: 20645684
    [No Abstract]   [Full Text] [Related]  

  • 50. [Cancer of the prostate: therapeutic strategy in 1985].
    Caty A; Cappelaere P; Demaille A
    Bull Cancer; 1986; 73(1):81-4. PubMed ID: 3779126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
    Pisansky TM
    Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of patients treated by radiation therapy for clinically-localized prostate cancer.
    Eapen L
    Can J Oncol; 1994 Nov; 4 Suppl 1():31-2. PubMed ID: 8853486
    [No Abstract]   [Full Text] [Related]  

  • 53. [Prostate cancer: has local radiation treatment had an impact on survival?].
    Chauvet B; Alfonsi M; de Rauglaudre G; Reboul F
    Cancer Radiother; 2002 May; 6(3):141-6. PubMed ID: 12116838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Organ preservation in the management of bladder and prostate cancer.
    Vitale V
    Rays; 1997; 22(3):406-9. PubMed ID: 9446944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy.
    Losa A; Nava LD; Di Muzio N; Mangili P; Longobardi B; Rigatti P; Guazzoni G
    Urology; 2003 Dec; 62(6):1068-72. PubMed ID: 14665357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Curative radiotherapy in stage C prostatic carcinoma. Experiences with radiotherapy-endocrine treatment].
    Klosterhalfen H; Becker H; Köllermann MW; Altenähr E
    Urologe A; 1983 Sep; 22 Suppl():360-6. PubMed ID: 6314624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adjuvant and neoadjuvant drug therapy for prostate cancer].
    Miller K; Lein M; Schostak M; Schrader M
    Urologe A; 2008 Nov; 47(11):1460-4. PubMed ID: 18813902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current studies of combined radiotherapy-hormone therapy in localized and locally advanced prostatic cancers].
    Bolla M; Artignan X; Chirpaz E; Balosso J; Descotes JL
    Cancer Radiother; 1998 Dec; 2(6):783-6. PubMed ID: 9922789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate cancer--the therapeutic challenge of locally advanced disease.
    Blasko JC; Lange PH
    N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
    [No Abstract]   [Full Text] [Related]  

  • 60. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results.
    Zietman AL; Prince EA; Nakfoor BM; Shipley WU
    Urology; 1997 Mar; 49(3A Suppl):74-83. PubMed ID: 9123741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.